SymBio Pharmaceuticals Limited
San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 http://www.symbiopharma.com/

January 27, 2010

SymBio Pharmaceuticals Limited.
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

Bendamustine HCl (SyB L-0501) Approved in Singapore and Hong Kong
- Gains Momentum for Business Expansion in Asia Pacific -

TOKYO, Japan, January 27, 2010 -- SymBio Pharmaceuticals Limited ("SymBio") today announced that the Health Sciences Authority (HSA) in Singapore approved bendamustine HCl (SyB L-0501) for the treatment of patients with indolent non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) on January 20, 2010 after receiving approval for the same two indications by the Department of Health (DH) in Hong Kong on December 30, 2009.

A third New Drug Application (NDA) for bendamustine HCl was submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan under priority review on October 30, 2009 after receiving orphan drug designation for the treatment of refractory and relapsed indolent NHL and mantle cell lymphoma.

The establishment of SymBio's business presence in the Asia Pacific region continues to gain momentum with the achievement of important milestones as pieces of the company's strategic development and commercialization plans in these key markets fall into place.
Preparations for the launch and marketing/sales of bendamustine HCl in Singapore are now underway by Eisai Co., Ltd.

[SyB L-0501]
SymBio holds exclusive rights to SyB L-0501, the Company's first drug candidate, from Astellas Deutschland GmbH for development and commercialization in Japan, China (HK), Taiwan, Korea and Singapore. SymBio and Eisai executed a license agreement for co-development and commercialization of SyB L-0501 in Japan in August, 2008, followed by a second license agreement for the exclusive development and commercialization of SyB L-0501 in Korea and Singapore in May, 2009. SymBio and Cephalon executed a license agreement for development and commercialization of SyB L-0501 in China in March, 2009, (Development and commercialization rights of bendamustine HCI are held by Cephalon, Inc. in North America, and by Mundipharma International Corp. Ltd. in Europe.) The drug is currently on the market in the U.S., and is listed as first line therapy for indolent NHL and mantle cell lymphoma in the NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology, the recognized standard for clinical policy in oncology.

[Company Profile]
SymBio Pharmaceuticals Ltd. was established in March, 2005 by Fuminori Yoshida, who previously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan (currently Takeda Bio Development Center Limited). The company's underlying corporate mission is "delivering hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in the Asia Pacific Rim dedicated to addressing underserved medical needs in the areas of oncology and hematology.

[Contact]
SymBio Pharmaceuticals Limited.
Hiroki Maekawa,
Corporate Officer,
Head of Corporate Division
Tel: +081(0)3 5472 1125
e-mail: Please send your inquiry through "INQUIRY" in our homepage
URL: http://www.symbiopharma.com/